Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4520
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis.

    To find out more about Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
A&G Pharmaceutical
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Amphora
Anavex Life Sciences
AndroBioSys
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Arana Therapeutics
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Bioenvision
Biogen Idec
Biokine Therapeutics
BioLineRx
BioMarin
BioNetWorks
BioNumerik
BioSante
Biostar
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Chong Kun Dang
Choongwae
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
CLL Pharma
Colby
Coronado Biosciences
Cosmo Bioscience
Critical Outcome Technologies
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Dong-A
Dongkook Pharm
Dyax
ECI
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
ExonHit Therapeutics
Ferring
Five Prime Therapeutics
Formula Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
GammaCan
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Got-a-Gene
GP Pharm
Gradalis
Green Cross
GTx
Hanmi
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innovive
Inovio
Insmed
Insys Therapeutics
Intezyne Technologies
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAI Pharmaceuticals
Karo Bio
Karus Therapeutics
Kiadis
Kinex
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mojave Therapeutics
Molecular Insight
MolMed
Mologen
Morvus Technology
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novelix
Novogen
Noxxon
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Pro-Pharmaceuticals
Progen
Progen Pharmaceuticals
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Sareum
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
ShimodaAtlantic Oncology
Shionogi
Shire
Siena Biotech
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Soligenix
Sophiris Bio
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
Twinstrand Therapeutics
UCB
Unigene
United Biomedical
Valeant
Vaxon Biotech
VaxOnco
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroTarg
VM Discovery
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEZS-108
afatinib
aflibercept
ALT-801
alvocidib
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
Angiozyme
apatinib
APC-100
APR-246
ARC-100
ARQ-197
astuprotimut-r
atrasentan
AVX-701
axitinib
bafetinib
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
bicalutamide
BMS-690514
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
brivanib alaninate
buserelin
Cabozantinib
canfosfamide hydrochloride
carlumab
cediranib
celecoxib
cetuximab
cilengitide
cixutumumab
crizotinib
custirsen
dacomitinib
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
E-7820
emepepimut-S
endostatin
ENMD-2076
entinostat
enzastaurin hydrochloride
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
etoposide (1)
etoposide phosphate
everolimus
Exherin
figitumumab
flutamide
foretinib
fosbretabulin tromethamine
fulvestrant
gataparsen
GDC-0980
gefitinib
GliaAtak
goserelin
GT-111
GTx-758
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
histrelin
icotinib hydrochloride
icrucumab
idronoxil
imatinib mesilate
inecalcitol
iniparib
INSM-18
interferon (gamma1b)
interleukins
intetumumab
ipilimumab
IPP-204106
irinotecan hydrochloride
irosustat
ispinesib mesylate
JI-101
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
linifanib
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
MGCD-265
midostaurin
MLN-8237
motesanib diphosphate
muparfostat (IV)
Nab-docetaxel
nadroparin
necitumumab
NGR-TNF
nilutamide
nimotuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
ON-01910
orteronel
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pazopanib hydrochloride
PCI-27483
pegdinetanib
pemetrexed disodium
perifosine
pertuzumab
PF-4856884
plitidepsin
PLX-3397
ponatinib
ProstAtak
PROSTVAC
PRX-302
PTC-299
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
SU-6668
sunitinib malate
TAK-448
talactoferrin alfa
tandutinib
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
thymalfasin
tipifarnib
tivozanib
TOK-001
topotecan
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
vismodegib
volociximab
XL-184
XL-647
YM-155
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis.
    To find out more about Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Learn More